Precigen, Inc. Gross Margin

Gross Margin of PGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending September 29, 2021 was 28.34% (a -48.69% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by -1.15%
  • Annual Gross Margin for 2020 was 46.2% (a 42.95% increase from previous year)
  • Annual Gross Margin for 2019 was 32.32% (a -44.79% decrease from previous year)
  • Annual Gross Margin for 2018 was 58.54% (a -19.61% decrease from previous year)
  • Twelve month Gross Margin ending September 29, 2021 was 42.16% (a -7.46% decrease compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by -8.74% year-over-year
Trailing Gross Margin for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
42.16% 45.56% 43.93% 46.2%
Visit stockrow.com/PGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Precigen, Inc.

Most recent Gross Marginof PGEN including historical data for past 10 years.

Interactive Chart of Gross Margin of Precigen, Inc.

Precigen, Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 28.34% 55.23% 47.06%
2020 28.67% 44.08% 50.99% 54.34% 46.2%
2019 9.36% 21.0% 49.08% 34.41% 32.32%
2018 60.04% 52.77% 59.06% 61.4% 58.54%
2017 78.52% 67.37% 69.05% 70.58% 72.82%
2016 68.78% 69.46% 67.46% 64.93% 67.72%
2015 63.95% 68.77% 59.31% 58.53% 63.18%
2014 59.37% 69.15% 99.55% 99.58% 73.22%
2013 100.0% 100.0% 100.0% 100.0% 99.91%
2012 100.0% 100.0% 100.0%
2011 100.0%

Business Profile of Precigen, Inc.

Sector: Healthcare
Industry: Biotechnology
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.